Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy

被引：1
|
作者：
Jensen, B. V.
Schou, J. V.
Johannesen, H. H.
Christensen, I. J.
Nielsen, D.
Johansen, J. S.
Hogdall, E. V.
Larsen, O.
Yilmaz, M.
Pfeiffer, P.
机构：
[1] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Radiol, DK-2730 Herlev, Denmark
[4] Univ Copenhagen, Finsen Inst, Copenhagen, Denmark
[5] Univ Copenhagen, Herlev Hosp, Dept Oncol, Copenhagen, Denmark
[6] Univ Copenhagen, Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark
[7] Aalborg Hosp, Dept Oncol, Aalborg, Denmark
[8] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3573
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cetuximab/irinotecan/5-FU +/-oxaliplatin or FOLFOXIRI plus /- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study).
    Folprecht, Gunnar
    Mende, Marika
    Liersch, Torsten
    Bechstein, Wolf Otto
    Kohne, Claus-Henning
    Stein, Alexander
    Kunzmann, Volker
    Ghadimi, Michael
    Neumann, Ulf Peter
    Nilsson, Sven
    Koenig, Alexander
    Pession, Ursula
    Troja, Achim
    Glados, Manfred
    Kleiss, Mathias
    Ubbelohde, Ulrike
    Weitz, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Myoung Joo Kang
    Yong Sang Hong
    Kyu-pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Min-Hee Ryu
    Jae-Lyun Lee
    Heung Moon Chang
    Mi-Jung Kim
    Hee Jin Chang
    Yoon-Koo Kang
    Tae Won Kim
    Investigational New Drugs, 2012, 30 : 1607 - 1613
  • [43] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Kang, Myoung Joo
    Hong, Yong Sang
    Kim, Kyu-pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Chang, Heung Moon
    Kim, Mi-Jung
    Chang, Hee Jin
    Kang, Yoon-Koo
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1607 - 1613
  • [44] Epidermal Growth Factor Receptor Expression Discrepancies in Metastatic Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan-Based Chemotherapy Refractory to Irinotecan and Oxaliplatin
    Han, Hye-Suk
    Chang, Hee Jin
    Hong, Yong Sang
    Kim, Sun Young
    Lee, Keun Seok
    Jung, Kyung Hae
    DISEASES OF THE COLON & RECTUM, 2009, 52 (06) : 1144 - 1151
  • [45] Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer
    Yamaguchi, Toshifumi
    Iwasa, Satoru
    Nagashima, Kengo
    Ikezawa, Nobuaki
    Hamaguchi, Tetsuya
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Okita, Natsuko
    Kato, Ken
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2016, 36 (07) : 3531 - 3536
  • [46] Recent progress in the treatment of colorectal cancer: Variations on the theme 5-FU, irinotecan and oxaliplatin-S
    Giacchetti, S
    EUROCANCER 96 - PROCEEDINGS OF THE NINTH CONGRESS, 1996, : 149 - 151
  • [47] A phase II study of cetuximab (Erbitux®) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Chang, Heung Moon
    Ryu, Min-Hoe
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 : S98 - S103
  • [48] Cetuximab and irinotecan in patients with EGFR plus colorectal cancer refactory to oxaliplatin and irinotecan: A single institution experience
    Herrero, A
    Alonso, V
    Lao, J
    de Lobera, AR
    Pazo, R
    Martinez-Trufero, J
    Puertolas, T
    Calderero, V
    Artal, A
    Anton, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 302S - 302S
  • [49] Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
    Hiroshi Soeda
    Hideki Shimodaira
    Mika Watanabe
    Takao Suzuki
    Makio Gamoh
    Takahiro Mori
    Keigo Komine
    Noriyuki Iwama
    Shunsuke Kato
    Chikashi Ishioka
    International Journal of Clinical Oncology, 2013, 18 : 670 - 677
  • [50] Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
    Soeda, Hiroshi
    Shimodaira, Hideki
    Watanabe, Mika
    Suzuki, Takao
    Gamoh, Makio
    Mori, Takahiro
    Komine, Keigo
    Iwama, Noriyuki
    Kato, Shunsuke
    Ishioka, Chikashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 670 - 677
12345